2011
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, . Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase. Diabetes Care 2011, 34: 2403-2405. PMID: 21933908, PMCID: PMC3198292, DOI: 10.2337/dc11-1248.Peer-Reviewed Original ResearchEffectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study
Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV. Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatric Diabetes 2011, 13: 6-11. PMID: 21722284, DOI: 10.1111/j.1399-5448.2011.00793.x.Peer-Reviewed Original ResearchConceptsType 1 diabetesSensor-augmented pump therapyA1C valuesSAP groupMDI groupPump therapyA1C targetsSAP therapyHyperglycemic excursionsMultiple daily injection therapyBaseline A1C valuesRisk of hypoglycemiaA1C reductionInjection therapyPediatric patientsGlycemic excursionsGlucose variabilityMDI therapyGlycemic variabilityLower AUC valuesTreatment groupsTherapyCGM studiesDiabetesAUC values
2008
Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2008, 153: 547-553.e3. PMID: 18589448, DOI: 10.1016/j.jpeds.2008.04.063.Peer-Reviewed Original ResearchConceptsInsulin glargineMultiple daily injectionsMultiple daily injection regimensType 1 diabetes mellitusBaseline A1C valuesDaily insulin glargineParallel group comparisonIntermediate acting insulinIntermediate-acting insulinOccurrence of hypoglycemiaPrandial insulin lisproOverall mean changeElevated A1C.MDI regimenMDI regimensBaseline A1CInjection regimensWeek 24Adverse eventsDiabetes mellitusHemoglobin A1cPediatric patientsSevere hypoglycemiaDaily injectionsA1C values